LinkedIn Profile

Access Adverum Biotechnologies historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:advm 10658023 Apr 21st, 2024 12:00AM Adverum Biotechnologies 10K 140.00 Open Apr 20th, 2024 10:46PM Apr 20th, 2024 10:46PM Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. Open Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina Open 100 Cardinal Way Redwood City California US 94063 Adverum Biotechnologies Health Care Equipment & Services
nasdaq:advm 10658023 Apr 20th, 2024 12:00AM Adverum Biotechnologies 10K 140.00 Open Apr 19th, 2024 10:37PM Apr 20th, 2024 04:29PM Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. Open Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina Open 100 Cardinal Way Redwood City California US 94063 Adverum Biotechnologies Health Care Equipment & Services
nasdaq:advm 10658023 Apr 19th, 2024 12:00AM Adverum Biotechnologies 10K 140.00 Open Apr 18th, 2024 10:45PM Apr 18th, 2024 10:45PM Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. Open Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina Open 100 Cardinal Way Redwood City California US 94063 Adverum Biotechnologies Health Care Equipment & Services
nasdaq:advm 10658023 Apr 18th, 2024 12:00AM Adverum Biotechnologies 10K 140.00 Open Apr 17th, 2024 10:44PM Apr 18th, 2024 05:49PM Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. Open Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina Open 100 Cardinal Way Redwood City California US 94063 Adverum Biotechnologies Health Care Equipment & Services
nasdaq:advm 10658023 Apr 17th, 2024 12:00AM Adverum Biotechnologies 10K 140.00 Open Apr 16th, 2024 10:35PM Apr 17th, 2024 02:12PM Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. Open Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina Open 100 Cardinal Way Redwood City California US 94063 Adverum Biotechnologies Health Care Equipment & Services
nasdaq:advm 10658023 Apr 16th, 2024 12:00AM Adverum Biotechnologies 10K 140.00 Open Apr 15th, 2024 10:34PM Apr 16th, 2024 10:29AM Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. Open Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina Open 100 Cardinal Way Redwood City California US 94063 Adverum Biotechnologies Health Care Equipment & Services
nasdaq:advm 10658023 Apr 15th, 2024 12:00AM Adverum Biotechnologies 10K 140.00 Open Apr 14th, 2024 10:36PM Apr 15th, 2024 04:10PM Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. Open Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina Open 100 Cardinal Way Redwood City California US 94063 Adverum Biotechnologies Health Care Equipment & Services
nasdaq:advm 10658023 Apr 14th, 2024 12:00AM Adverum Biotechnologies 10K 140.00 Open Apr 13th, 2024 10:30PM Apr 14th, 2024 10:29AM Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. Open Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina Open 100 Cardinal Way Redwood City California US 94063 Adverum Biotechnologies Health Care Equipment & Services
nasdaq:advm 10658023 Apr 13th, 2024 12:00AM Adverum Biotechnologies 10K 140.00 Open Apr 12th, 2024 10:21PM Apr 13th, 2024 10:57AM Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. Open Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina Open 100 Cardinal Way Redwood City California US 94063 Adverum Biotechnologies Health Care Equipment & Services
nasdaq:advm 10658023 Apr 12th, 2024 12:00AM Adverum Biotechnologies 10K 140.00 Open Apr 11th, 2024 10:24PM Apr 12th, 2024 07:52AM Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. Open Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina Open 100 Cardinal Way Redwood City California US 94063 Adverum Biotechnologies Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.